Abstract
Background/Objectives
Orodispersible films (ODFs) are increasingly proposed as patient-centered oral dosage forms, yet evidence on how adult men perceive them is scarce. This cross-sectional study assessed anticipated acceptability, willingness to choose the film version, and purchase intention for placebo ODFs prepared with OrPhyllo™ (an orodispersible film-forming base; Fagron BV, Rotterdam, The Netherlands) among 100 men aged 19–79 years recruited in Juiz de Fora, Brazil. All assessments were based exclusively on visual and tactile inspection, without oral administration.
Methods
Participants handled and inspected a 3 × 3 cm placebo film and completed a structured, investigator-administered questionnaire.
Results
Mean age was 30.7 ± 13.6 years and mean body mass index 25.0 ± 4.7 kg/m2; 48.0% had excess body weight and 43.0% reported difficulty swallowing tablets, either personally or in someone under their care. Prior awareness of ODFs was moderate (49.0%), but only 10.0% had ever used one. All participants reported a favorable overall impression, 70.0% would choose the film version of a medication they used, and 54.0% would purchase it; high cost was the most frequently selected potential deterrent to use (67.0%). In univariate analyses, firm purchase intention (“would purchase”) was associated with reported difficulty swallowing tablets in oneself or someone under their care (51.9% vs 32.6%; p = 0.049) and with rating the film as pleasant in appearance (p = 0.04), smooth in texture (p = 0.01), and adequate in size (p = 0.004), but not with any sociodemographic variable or with prior familiarity with ODFs. After adjustment, only perceived adequate size remained independently associated with firm purchase intention (odds ratio 4.37; 95% confidence interval 1.11–17.22; p = 0.035); smooth texture (2.35; 0.99–5.59) and reported swallowing difficulty (1.97; 0.83–4.69) did not reach significance. The model was well calibrated (Hosmer–Lemeshow p = 0.50) but of modest explanatory capacity (Nagelkerke R2 = 0.18; apparent accuracy 70.0%).
Conclusions
Anticipated acceptability of placebo ODFs among men was high and largely unrelated to the sociodemographic profile measured, being instead associated with the physical attributes of the film. Because the films were not administered orally and actual purchasing behavior was not observed, these hypothesis-generating findings reflect anticipated rather than actual acceptability and stated rather than observed purchasing behavior, and require confirmation in studies involving oral administration.
Keywords: orodispersible film, oral thin film, patient acceptability, patient preference, purchase intention, men’s health
Introduction
Men engage with healthcare services less frequently than women, tend to present later in the course of disease, and are less likely to sustain long-term treatment.1,2 Sociocultural norms surrounding self-reliance, reluctance to seek help, and the stigma attached to perceived vulnerability contribute to this pattern and are now recognized as legitimate targets for health-system intervention.3 Because these barriers operate during everyday medication use as much as at the point of care, the design of the medicine itself — how it is carried, handled, and taken — is a plausible, if under-investigated, lever for improving engagement among men.
Dosage-form characteristics influence acceptability, usability, and, ultimately, adherence: convenience, ease of administration, and sensory acceptance all shape the treatment experience.4,5 Orodispersible films (ODFs) are thin, flexible polymeric strips that disintegrate rapidly on contact with saliva and release the incorporated ingredient locally or systemically without the need for water.4 They are portable, discreet, and simple to administer, and have been proposed as patient-centered alternatives to tablets and capsules for people who find conventional solid oral dosage forms difficult to swallow.5,6
Compared with orally disintegrating tablets (ODTs), ODFs provide a thin and flexible dosage form that disintegrates in the oral cavity without water and may reduce concerns related to tablet friability and choking. However, ODFs generally accommodate lower drug doses than ODTs, and their performance and acceptability remain dependent on formulation characteristics, including adequate mechanical properties, taste, texture, and mouthfeel.7,8
Research on ODF acceptability has concentrated on the populations in whom swallowing difficulty is most prevalent, namely pediatric and geriatric patients.5,6 Nevertheless, a small number of human-panel studies in adults have shown that ODF acceptability is influenced by formulation and sensory attributes such as stickiness, disintegration time, film size and thickness, handling, and mouthfeel. These studies, conducted largely in healthy adult volunteers, have provided useful insight into how the physical and sensory characteristics of ODFs shape end-user perception, although evidence in specific adult patient populations remains limited.9–11 Adult men have rarely been studied as a group in their own right, even though they represent a substantial share of the market for the conditions in which ODFs are most often positioned. The present study deliberately focused on men rather than undertaking a comparison between sexes because its objective was not to determine sex-based differences in ODF perception, but to characterize acceptability and preferences within a population that is underrepresented in this area of research and that may face distinct barriers to healthcare engagement and long-term treatment use. This gap matters because bringing a new dosage form to market requires more than proof of efficacy: understanding how the intended user perceives the product is a strategic step in pharmaceutical research and development, allowing the technical formulation to be aligned with the expectations and needs of the target audience.5,6
We therefore conducted a cross-sectional study to characterize visual and tactile perceptions, anticipated acceptability, willingness to choose the film version, and purchase intention for placebo ODFs among adult men, and to explore which participant and product attributes were associated with firm purchase intention (“would purchase” vs all other purchase-intention responses).
Materials and Methods
Study Design and Setting
This was a quantitative, cross-sectional, single-visit study conducted in Juiz de Fora, Minas Gerais, Brazil. Participants were recruited by convenience sampling at the Federal University of Juiz de Fora (UFJF) and at other workplace and educational settings in the same city. The study was conducted in accordance with the Declaration of Helsinki and approved by the Human Research Ethics Committee of UFJF (CAAE: 93677825.1.0000.5147). Written informed consent was obtained from every participant before any study procedure. Reporting follows the STROBE recommendations for cross-sectional studies.
Participants
Eligible participants were men aged 18–79 years, irrespective of race/ethnicity, sexual orientation, gender identity, or socioeconomic background. The broad adult age range was intentionally selected to capture perceptions across different stages of adulthood and to increase the heterogeneity of the sample in this exploratory study. Age was therefore evaluated as a continuous variable in the analyses rather than by predefined age categories. Individuals judged by the investigator to be unable to understand the oral study explanation during the informed consent process, and those who did not provide written informed consent, were excluded. Because the study was exploratory and hypothesis-generating, no formal sample size calculation was performed; a convenience sample of 100 men who completed the entire questionnaire was analyzed.
Placebo Orodispersible Films
Placebo ODFs were prepared using OrPhyllo™ (orodispersible film-forming base; Fagron BV, Rotterdam, The Netherlands) according to previously published methods.11–13 Briefly, the film-forming base was reconstituted with purified water and the accompanying excipients, and mannitol was incorporated as an inactive ingredient. The resulting paste was cast onto glass plates, dried at 40 °C for 40 min, cut into 3 × 3 cm squares, and packaged individually in matte laminated aluminum sachets. The casting and drying process yields films with one smooth and one rough surface. The films contained no active pharmaceutical ingredient. The 3 × 3 cm dimensions were selected because this is an established film size used within this compounding platform and has been employed in previously published studies using the same preparation method.11,12
Evaluation Procedure and Questionnaire
Before the evaluation, all participants were informed that the ODF would not be administered and received standardized instructions on how to inspect it. Each participant was given one sachet, which he opened himself; he then removed the film, handled it, bent it, and visually inspected both surfaces. All assessments were therefore based exclusively on visual and tactile examination of the packaging, dimensions, appearance, surface texture, and flexibility of the film, without oral administration. Accordingly, the construct evaluated in this study was anticipated acceptability based on visual and tactile perception rather than acceptability following actual oral administration.
Responses were recorded on a structured, investigator-administered questionnaire developed specifically for this exploratory study (Supplementary Material S1). The questionnaire was reviewed during protocol development by a physician involved in the study design; however, it was not pilot-tested or subjected to formal psychometric validation or reproducibility testing. The first section captured sociodemographic and clinical variables: age, self-reported race/skin color, educational level, family income expressed in Brazilian minimum wages, employment status, marital status, smoking status, body mass index (BMI), reported difficulty swallowing tablets, either personally or in someone under the participant’s care, and prior awareness and previous use of ODFs. BMI was classified according to World Health Organization cut-offs. The second section assessed perceptions of, and preferences for, the film using closed-ended items covering appearance (pleasant/unpleasant), texture (smooth/rough), size (adequate/inadequate), ease of carrying (easy/difficult), ease of use (easy/difficult), overall impression, willingness to choose the film version if a medication already used by the participant were available in that form, potential factors that could discourage use, and purchase intention. Potential factors that could discourage use were assessed by asking participants what would discourage them from using the film, with response options including lack of information, unpleasant taste, high cost, and distrust in efficacy. These items represented anticipated concerns rather than attributes directly experienced during the evaluation.
Outcome Definition
The outcome of interest was purchase intention, recorded on a four-category verbal scale (would purchase / would probably purchase / might or might not purchase / would probably not purchase). For analysis, the outcome was dichotomized into firm purchase intention (the unqualified response “would purchase”) vs all other purchase-intention responses, on the grounds that only the top category of verbal intention scales is consistently predictive of behavior, whereas the intermediate categories are known to over-predict it.
Statistical Analysis
Continuous variables are summarized as mean ± standard deviation (SD) and categorical variables as absolute frequency (n) and percentage (%). Participants who responded “would purchase” were compared with those who selected any of the other purchase-intention categories using Student’s t-test for continuous variables and Pearson’s chi-square test for categorical variables.
Variables associated with firm purchase intention at p ≤ 0.05 in the univariate analysis were considered as candidate predictors for a binary logistic regression model. Perceived appearance could not be entered, because all 54 participants with a firm purchase intention rated the appearance as pleasant, producing a zero cell and separation of the outcome. The remaining candidates (perceived size, perceived texture, and reported difficulty swallowing tablets in oneself or someone under their care) were entered and a stepwise elimination procedure was applied; predictors that did not reach p ≤ 0.05 in the multivariable model were nevertheless retained on the grounds of a priori plausibility and because their inclusion improved model fit. With 54 events and three predictors, the model comfortably exceeded the conventional minimum of ten events per variable. Model performance was assessed using the model chi-square, the −2 log-likelihood, Nagelkerke’s R2, the Hosmer–Lemeshow goodness-of-fit test, and the classification table at the default 0.5 probability cut-off; the reported classification performance is apparent (in-sample), as no internal validation was performed. Results are presented as parameter estimates (B) with standard errors (SE), odds ratios (OR), and 95% confidence intervals (CI).
All analyses were performed in IBM SPSS Statistics for Windows, version 24.0 (IBM Corp., Armonk, NY, USA). Two-sided p ≤ 0.05 was considered statistically significant. Given the exploratory nature of the study, p-values were not adjusted for multiple comparisons and should be interpreted as hypothesis-generating.
Results
Sociodemographic Characteristics
One hundred men aged 19–79 years (mean 30.7 ± 13.6) were included, of whom 73.0% self-identified as white. Mean BMI was 25.0 ± 4.7 kg/m2, and 48.0% had excess body weight (34.0% overweight, 12.0% obesity class I, and 2.0% obesity class III). Most participants were highly educated: 57.0% had completed higher education and a further 26.0% held a postgraduate qualification. Three-quarters (74.0%) were unmarried, and family income was distributed across all categories, with 37.0% reporting <3, 26.0% reporting 3–6, and 37.0% reporting >6 Brazilian minimum wages. Difficulty swallowing tablets, either personally or in someone under their care, was reported by 43.0% of participants. Almost half (49.0%) were already aware of ODFs, but only 10.0% had ever used one; among those ten men, the most frequent purpose of previous use was bad breath (5/10). The full characteristics of the sample are presented in Table 1.
Table 1.
Sociodemographic Characteristics and Personal History of Orodispersible Film (ODF) Use Among the Study Participants (n = 100)
| Characteristic | Mean ± SD or n (%) |
|---|---|
| Age (years) | 30.7 ± 13.6 |
| Body mass index (kg/m2) | 25.0 ± 4.7 |
| Underweight | 5 (5.0) |
| Normal weight | 47 (47.0) |
| Overweight | 34 (34.0) |
| Obesity class I | 12 (12.0) |
| Obesity class II | 0 (0.0) |
| Obesity class III | 2 (2.0) |
| Educational level | |
| High school | 17 (17.0) |
| Higher education | 57 (57.0) |
| Postgraduate education | 26 (26.0) |
| Self-reported race/skin color | |
| White | 73 (73.0) |
| Brown (pardo) | 22 (22.0) |
| Black | 5 (5.0) |
| Family income | |
| <3 minimum wages | 37 (37.0) |
| 3–6 minimum wages | 26 (26.0) |
| >6 minimum wages | 37 (37.0) |
| Currently employed (yes) | 43 (43.0) |
| Marital status | |
| Married | 26 (26.0) |
| Unmarried | 74 (74.0) |
| Current smoker (yes) | 11 (11.0) |
| Reported difficulty swallowing tablets (self or someone under their care) | 43 (43.0) |
| Prior awareness of ODFs (yes) | 49 (49.0) |
| Previous use of an ODF (yes) | 10 (10.0) |
| Purpose of previous usea | |
| Bad breath | 5 (50.0) |
| Nausea | 1 (10.0) |
| Other | 4 (40.0) |
Notes: aPercentages were calculated among the 10 participants who had previously used an ODF. Nausea was reported as a free-text response under the “Other” option. Response categories of the questionnaire for educational level, family income, and marital status (Supplementary Material S1) were collapsed for analysis.
Abbreviations: SD, standard deviation; ODF, orodispersible film.
Perceptions of the Orodispersible Film
Perceptions of the film were uniformly favorable (Table 2). Nearly all participants rated its appearance as pleasant (96.0%) and its size as adequate (85.0%), and considered it easy to carry (98.0%) and easy to use (99.0%); the surface was described as smooth by 59.0% and as rough by 41.0%. All participants (100.0%) reported a favorable overall impression. Seventy percent stated that they would choose the film version if a medication they used were available in that form, 28.0% answered “maybe”, and 2.0% answered “no”.
Table 2.
Male Participants’ Perceptions of the Characteristics of the Orodispersible Film (ODF) (n = 100)
| Attribute | n (%) |
|---|---|
| Appearance | |
| Pleasant | 96 (96.0) |
| Unpleasant | 4 (4.0) |
| Texture | |
| Smooth | 59 (59.0) |
| Rough | 41 (41.0) |
| Size | |
| Adequate | 85 (85.0) |
| Inadequate | 15 (15.0) |
| Ease of carrying | |
| Easy | 98 (98.0) |
| Difficult | 2 (2.0) |
| Ease of use | |
| Easy | 99 (99.0) |
| Difficult | 1 (1.0) |
| Overall impression | |
| Favorable | 100 (100.0) |
| Unfavorable | 0 (0.0) |
| Would choose the film version if a medication used were available as an ODF | |
| Yes | 70 (70.0) |
| Maybe | 28 (28.0) |
| No | 2 (2.0) |
| Purchase intention | |
| Would purchase | 54 (54.0) |
| Would probably purchase | 32 (32.0) |
| Might or might not purchase | 13 (13.0) |
| Would probably not purchase | 1 (1.0) |
Abbreviation: ODF, orodispersible film.
Purchase Intention and Potential Discouraging Factors
Just over half of the participants (54.0%) reported that they would purchase the ODF, 32.0% that they would probably purchase it, 13.0% that they might or might not purchase it, and 1.0% that they would probably not purchase it. The most frequently selected potential factor that could discourage use was high cost, cited by 67.0% of participants; lack of information, unpleasant taste, and distrust in efficacy were also selected. These responses represented anticipated concerns rather than direct experience: participants were not presented with a specific price and did not administer the film orally or assess its taste (Figure 1).
Figure 1.

Potential factors reported by participants as discouraging use of the orodispersible film (n = 100).
Factors Associated with Firm Purchase Intention
Compared with participants selecting other purchase-intention responses, those who stated that they would purchase the ODF more frequently reported difficulty swallowing tablets in themselves or someone under their care (51.9% vs 32.6%; p = 0.049) and rated the film more favorably in terms of appearance (pleasant: 100.0% vs 91.3%; p = 0.04), texture (smooth: 70.4% vs 45.7%; p = 0.01), and size (adequate: 94.4% vs 73.9%; p = 0.004). Firm purchase intention was not associated with age, educational level, family income, marital status, smoking status, prior awareness or previous use of ODFs, or with selecting high cost as a potential discouraging factor (all p > 0.05; Table 3).
Table 3.
Univariate Comparison According to Firm Purchase Intention for the Orodispersible Film (ODF) (n = 100)
| Variable | Firm Purchase Intention (“Would Purchase”) (n = 54) | All Other Responses (n = 46) | p-value |
|---|---|---|---|
| Age (years), mean ± SD | 32.7 ± 15.8 | 28.3 ± 10.1 | 0.10 |
| Educational level, n (%) | 0.49 | ||
| High school | 11 (20.4) | 6 (13.0) | |
| Higher education | 31 (57.4) | 26 (56.5) | |
| Postgraduate education | 12 (22.2) | 14 (30.4) | |
| Family income, n (%) | 0.39 | ||
| <3 minimum wages | 19 (35.2) | 18 (39.1) | |
| 3–6 minimum wages | 17 (31.5) | 9 (19.6) | |
| >6 minimum wages | 18 (33.3) | 19 (41.3) | |
| Marital status, n (%) | 0.54 | ||
| Married | 16 (29.6) | 10 (21.7) | |
| Unmarried | 38 (70.4) | 36 (78.3) | |
| Current smoker, n (%) | 7 (13.0) | 4 (8.7) | 0.49 |
| Reported difficulty swallowing tablets (self or someone under their care), n (%) | 28 (51.9) | 15 (32.6) | 0.049 * |
| Prior awareness of ODFs, n (%) | 24 (44.4) | 25 (54.3) | 0.32 |
| Previous use of an ODF, n (%) | 4 (7.4) | 6 (13.0) | 0.35 |
| Appearance rated pleasant, n (%) | 54 (100.0) | 42 (91.3) | 0.04 * |
| Texture rated smooth, n (%) | 38 (70.4) | 21 (45.7) | 0.01 * |
| Size rated adequate, n (%) | 51 (94.4) | 34 (73.9) | 0.004 * |
| High cost selected as a potential discouraging factor, n (%) | 39 (72.2) | 28 (60.9) | 0.23 |
Notes: Data are n (%) unless otherwise stated. The “all other responses” group comprises the “would probably purchase”, “might or might not purchase”, and “would probably not purchase” categories. Student’s t-test was used for continuous variables and Pearson’s chi-square test for categorical variables. *p ≤ 0.05.
Abbreviations: ODF, orodispersible film; SD, standard deviation.
In the multivariable logistic regression (Table 4), perceived adequate size was the only predictor independently associated with firm purchase intention: participants who considered the film size adequate had approximately four-fold higher odds of stating that they would purchase it (OR 4.37; 95% CI 1.11–17.22; p = 0.035). Perceived smooth texture (OR 2.35; 95% CI 0.99–5.59; p = 0.054) and reported difficulty swallowing tablets in oneself or someone under their care (OR 1.97; 95% CI 0.83–4.69; p = 0.125) were retained in the model, but their confidence intervals included the null value. The model was globally significant (χ2 = 14.937; p = 0.002) and well calibrated (Hosmer–Lemeshow p = 0.50), but explained only a modest fraction of the variance in purchase intention (Nagelkerke R2 = 0.18). At the 0.5 cut-off, apparent sensitivity was 83.3%, apparent specificity 54.3%, and overall apparent classification accuracy 70.0%.
Table 4.
Multivariable Binary Logistic Regression Model for the Probability of Firm Purchase Intention (“Would Purchase”) for the Orodispersible Film (n = 100)
| Predictor | B | SE | p-value | OR (95% CI) |
|---|---|---|---|---|
| Reported difficulty swallowing tablets (self or someone under their care) (yes) | 0.678 | 0.442 | 0.125 | 1.97 (0.83–4.69) |
| Size rated adequate | 1.476 | 0.699 | 0.035 | 4.37 (1.11–17.22) |
| Texture rated smooth | 0.854 | 0.443 | 0.054 | 2.35 (0.99–5.59) |
| Constant | −1.896 | 0.691 | 0.006 | 0.15 |
Notes: B, parameter estimate; Model statistics: χ2 = 14.937, p = 0.002; −2 log-likelihood = 123.052; Nagelkerke R2 = 0.18; Hosmer–Lemeshow p = 0.50; apparent classification accuracy = 70.0% (sensitivity 83.3%, specificity 54.3%). Reference categories: reported difficulty swallowing tablets in oneself or someone under their care = no; size = inadequate; texture = rough.
Abbreviations: SE, standard error; OR, odds ratio; CI, confidence interval.
Discussion
In this cross-sectional evaluation, placebo ODFs were received favorably by adult men on the basis of visual and tactile inspection alone: every participant reported a favorable overall impression, 70.0% stated that they would choose the film version if a medication they used were available in that form, and 54.0% stated that they would purchase it. The variables associated with firm purchase intention were product-related — appearance, texture, and size — together with reported difficulty swallowing tablets in oneself or someone under the participant’s care, whereas no sociodemographic characteristic was associated with it. After adjustment, only perceived size remained independently associated with the outcome. These results support the view that the physical design of an ODF is not a cosmetic detail but a determinant of its anticipated acceptance, and that organoleptic and physical properties deserve explicit attention during the development of patient-centered oral dosage forms.
Perceived Size as the Dominant Attribute
The dominance of perceived size warrants comment. The films evaluated here measured 3 × 3 cm, an established size used within the same compounding platform and in previous studies of this formulation;11,12 films prepared with this platform can, however, be produced in other dimensions depending on formulation requirements and drug load. At 9 cm2, this format is larger than the approximately 2 × 2 cm generally considered acceptable for ODFs given the limited space in the oral cavity,14 which may partly explain why 15.0% of participants considered it inadequate; participants who did were markedly less likely to state that they would purchase the ODF. Film area is not a free parameter — it is constrained by drug loading and by the mechanical properties of the polymer matrix — yet it directly determines the perceived bulk of the dosage form in the mouth and the ease of handling it with dry fingers.4,15 The magnitude of the association should nevertheless be interpreted with caution: the estimate derives from only 15 participants who rated the size as inadequate, and the resulting confidence interval (1.11–17.22) is wide and compatible with anything from a marginal to a very large effect. The direction of the association is reasonably secure; its size is not.
Perceived smooth texture showed an effect of similar direction and moderate magnitude (OR 2.35) but did not reach conventional significance after adjustment (p = 0.054); with 54 events, the study was not powered to resolve effects of this order, and the result is better read as suggestive than as null. Perceived appearance could not be modelled because no participant with a firm purchase intention rated the film as unpleasant. More broadly, the near-uniform positive responses for appearance (96.0%), ease of carrying (98.0%), ease of use (99.0%), and overall impression (100.0%) indicate substantial ceiling effects. Because several acceptability items used dichotomous response options, these measures provided limited discrimination between participants and may have obscured more nuanced differences in perception. The restricted variability also reduced the usefulness of these variables for exploring associations with purchase intention and, in the case of appearance, prevented meaningful inclusion in the regression model. Future studies should consider graded response instruments, such as visual analogue or multi-category hedonic scales, to provide greater discriminatory capacity.
Reported Swallowing Difficulty and the Case for ODFs in Men
Difficulty swallowing tablets, either personally or in someone under the participant’s care, was reported by 43.0% of the sample. Because the questionnaire combined participants’ own swallowing difficulty with that of someone they cared for, this proportion should not be interpreted as the prevalence of dysphagia or tablet-swallowing difficulty among the men themselves. Participants reporting this circumstance were more likely to state that they would purchase the ODF in the univariate analysis, although the association attenuated after adjustment for product attributes (OR 1.97; 95% CI 0.83–4.69). Water-free, portable, and discreet administration is the principal practical argument for ODFs,4 and previous work in other therapeutic contexts has shown that patients may prefer orodispersible formulations to conventional tablets on grounds of convenience and ease of administration.16 Our data are consistent with that literature. They do not, however, establish that ODFs improve treatment initiation or adherence: no medication was administered, and no adherence outcome was measured. That remains a plausible hypothesis rather than a demonstrated benefit.
Potential Cost-Related Concerns
High cost was the most frequently selected potential factor that could discourage use (67.0%), yet selecting this option was not associated with firm purchase intention (72.2% vs 60.9%; p = 0.23). Because no specific price was presented, this response should be interpreted as an anticipated concern rather than an evaluation of the cost of the study product. The absence of an association suggests that cost is a salient concern that participants readily articulate when prompted, rather than a decisive determinant of stated intention in a hypothetical scenario in which no price was at stake. It follows that no willingness-to-pay threshold can be inferred from these data. Manufacturing route is a principal driver of the unit cost of ODFs, and continuous casting and printing technologies are being actively developed with cost reduction among their objectives.15 Willingness-to-pay studies incorporating explicit price points, formal economic evaluation, and analysis of supply-chain access are therefore needed before conclusions about affordability-related uptake can responsibly be drawn.
Absence of Sociodemographic Effects
No sociodemographic variable — age, educational level, family income, marital status, or smoking status — was associated with purchase intention, and neither prior awareness nor previous use of ODFs was associated with it. It is tempting to read this as evidence that acceptability is uniform across demographic strata, and hence that a single, well-designed ODF platform could serve a broad male population without segment-specific adaptation. That interpretation should be advanced cautiously. With 100 participants and 54 events, the study had limited power to detect modest subgroup differences, and the sample was demographically narrow: predominantly white (73.0%), young (mean age 30.7 years), and highly educated (83.0% with higher or postgraduate education). The absence of a detected association is not evidence of the absence of an association; demographic uniformity is a hypothesis generated by these data, not a conclusion supported by them, and it requires testing in a larger and more heterogeneous sample.
Implications for Formulation Development
Taken together, these findings support the position that patient acceptability should be treated as a critical quality attribute in galenic development, alongside established parameters such as stability, bioavailability, and bioequivalence. A therapeutically effective active pharmaceutical ingredient delivers limited benefit if the final dosage form is difficult to use or unappealing to the person expected to take it. The corollary for men’s health is specific: interventions designed for men must accommodate the contextual factors that shape their engagement with healthcare — accessibility, discretion, and alignment with everyday routines — as articulated in user-centered frameworks for men’s health programs17 and in the broader literature on gender-responsive, person-centered health systems.1,18–20 At the same time, the modest explanatory capacity of our model (Nagelkerke R2 = 0.18) indicates that the physical attributes measured here account for only a minority of the variation in stated purchase intention. Taste, flavor, disintegration behavior, price, therapeutic indication, and prescriber recommendation are plausible additional determinants that this study did not capture and that should be incorporated into subsequent work.
Limitations
Several limitations should be borne in mind. First, and most importantly, acceptability was anticipated rather than experienced: the films were inspected but not administered, so taste, mouthfeel, disintegration time, and oral residue — attributes known to drive real-world acceptance of ODFs — could not be assessed, and the outcome was stated intention rather than observed purchasing behavior. Although the study-specific questionnaire underwent clinical review during protocol development, it was not pilot-tested or formally psychometrically validated, and its reproducibility was not assessed. These limitations should be considered when interpreting the questionnaire-derived outcomes. Because the questionnaire was investigator-administered in a face-to-face setting immediately following presentation of the film, socially desirable responding cannot be excluded and may have contributed to the highly favorable ratings observed. This possibility may have been further amplified by the limited discrimination provided by dichotomous response options for several acceptability items. Second, the convenience sample of 100 men from a single Brazilian city was predominantly white, young, and highly educated, which limits generalizability to more ethnically and socioeconomically diverse populations. Selection bias associated with convenience recruitment also cannot be excluded. Third, the study was exploratory: no sample size calculation was performed, twelve univariate comparisons were made without adjustment for multiplicity, two of the significant associations were marginal (p = 0.049 and p = 0.04), and the logistic model was neither internally validated nor evaluated outside the sample in which it was fitted. The study was therefore not powered to detect associations of a predefined magnitude, so non-significant findings may reflect type II error, whereas the unadjusted comparisons mean that type I error cannot be excluded, particularly for the two associations close to the conventional significance threshold. Fourth, ceiling effects in the appearance and overall-impression items limited their analytical usefulness and prevented appearance from being modelled. Fifth, only men were studied, by design; it therefore cannot be determined whether the preferences observed are male-specific or shared with other groups, a question that requires a comparative design. Finally, the study was funded by the manufacturer of the film-forming base, which also provided the placebo films, and three authors are employees of that company; this potential conflict of interest is declared in full below. Given the involvement of company-affiliated authors, independent replication of these exploratory findings would further strengthen confidence in the results.
Future Directions
Longitudinal studies involving actual administration and observed adherence are needed to determine whether the favorable anticipated acceptability reported here translates into sustained use in clinical practice. Priorities include evaluation of active-containing films with defined taste-masking, elicitation of willingness to pay against explicit price points, formal cost-effectiveness analysis, and assessment in older men and men with chronic disease, in whom the clinical case for an alternative solid oral dosage form is strongest.
Conclusions
Placebo ODFs produced with OrPhylloTM were received favorably by adult men on visual and tactile inspection: all participants reported a favorable overall impression, 70.0% stated that they would choose the film version if a medication they used were available in that form, and 54.0% reported that they would purchase it. Anticipated acceptability was largely unrelated to the sociodemographic characteristics measured or to prior familiarity with the technology, whereas perceived film characteristics were associated with firm purchase intention. After adjustment, perceived adequate size was the only attribute independently associated with firm purchase intention, although the effect estimate was imprecise. High cost was the most frequently reported potential factor that could discourage use, but no specific price was presented to participants. Importantly, the film was not administered orally and actual purchasing behavior was not observed; therefore, the findings reflect anticipated perceptions and stated intentions rather than actual acceptability or purchasing behavior. These findings are hypothesis-generating and require confirmation in studies involving oral administration, direct assessment of sensory attributes, and observation of real-world behavior.
Acknowledgments
The authors gratefully acknowledge Fagron BV for providing the placebo orodispersible films used in this study.
Funding Statement
This study was funded by Fagron BV, which also provided the placebo orodispersible films used in the study.
Data Sharing Statement
The data supporting the findings of this study are available from the corresponding author upon reasonable request.
Ethics Approval and Informed Consent
The study was conducted in accordance with the Declaration of Helsinki and approved by the Human Research Ethics Committee of the Federal University of Juiz de Fora (approval no. CAAE: 93677825.1.0000.5147). Written informed consent was obtained from all participants involved in the study.
Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
Disclosure
H.C.P., C.C.V.S. and C.S.K. are employees of Fagron BV, which manufactures the film-forming base used in this study and provided the placebo films. Dr Nádia Raposo reports Royalties or licenses from Fagron, outside the submitted work. The remaining authors declare no conflict of interest. Fagron BV had no role in the design of the study; in the collection, analysis, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.
References
- 1.Seidler ZE, Benakovic R, Wilson MJ, McGee MA, Fisher K, Smith JA, Oliffe JL. Approaches to engaging men during primary healthcare encounters: a scoping review. Am J Mens Health. 2024;18(2). doi: 10.1177/15579883241241090 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Robertson LM, Douglas F, Ludbrook A, Reid G, van Teijlingen E. What works with men? A systematic review of health promoting interventions targeting men. BMC Health Serv Res. 2008;8(1):141. doi: 10.1186/1472-6963-8-141 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.World Health Organization. Reaching Men with Person-Centred Health Services Through Evidence-Based Approaches and Interventions. Geneva, Switzerland: World Health Organization; 2023. [Google Scholar]
- 4.Morath B, Sauer S, Zaradzki M, Wagner AH. Orodispersible films – recent developments and new applications in drug delivery and therapy. Biochem Pharmacol. 2022;200:115036. doi: 10.1016/j.bcp.2022.115036 [DOI] [PubMed] [Google Scholar]
- 5.Scarpa M, Stegemann S, Hsiao W-K, et al. Orodispersible films: towards drug delivery in special populations. Int J Pharm. 2017;523(1):327–11. doi: 10.1016/j.ijpharm.2017.03.018 [DOI] [PubMed] [Google Scholar]
- 6.Cornilă A, Iurian S, Tomuță I, Porfire A. Orally dispersible dosage forms for paediatric use: current knowledge and development of nanostructure-based formulations. Pharmaceutics. 2022;14(8):1621. doi: 10.3390/pharmaceutics14081621 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Irfan M, Rabel S, Bukhtar Q, Qadir MI, Jabeen F, Khan A. Orally disintegrating films: a modern expansion in drug delivery system. Saudi Pharm J. 2016;24(5):537–546. doi: 10.1016/j.jsps.2015.02.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Khan QUA, Siddique MI, Sarfraz M, Rehman K, Sohail MF, Katas H. Oral dispersible films from product development to end-user acceptability: a review. Crit Rev Ther Drug Carrier Syst. 2022;39(1):33–64. doi: 10.1615/CritRevTherDrugCarrierSyst.2021036885 [DOI] [PubMed] [Google Scholar]
- 9.Scarpa M, Paudel A, Kloprogge F, et al. Key acceptability attributes of orodispersible films. Eur J Pharm Biopharm. 2018;125:131–140. doi: 10.1016/j.ejpb.2018.01.003 [DOI] [PubMed] [Google Scholar]
- 10.Abdelhakim HE, Williams GR, Craig DQM, Orlu M, Tuleu C. Human mouthfeel panel investigating the acceptability of electrospun and solvent cast orodispersible films. Int J Pharm. 2020;585:119532. doi: 10.1016/j.ijpharm.2020.119532 [DOI] [PubMed] [Google Scholar]
- 11.Dziemidowicz K, Jin J, Ranmal SR, et al. Characterization and sensory evaluation of placebo OrPhylloTM orodispersible films as a versatile pediatric drug delivery platform. Drug Dev Ind Pharm. 2025:1–11. doi: 10.1080/03639045.2025.2521664 [DOI] [PubMed] [Google Scholar]
- 12.Polonini HC, Ferreira AO, Raposo NRB, da Silva PJLC, Brandão MAF. Compatibility Assessment of Novel Orodispersible Film Vehicle for Personalized Medicine with Selected Active Pharmaceutical Ingredients. J Pers Med. 2023;13(11):1565. doi: 10.3390/jpm13111565 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Polonini H, Marianni B, da Silva Rovai E, Aparecida Neves Jardini M, Magnoni Moretto Nunes C, Oliveira CR. Evaluation of in vitro toxicity of OrPhyllo™, a new vehicle to produce orodispersible films. Int J Toxicol. 2025;44(5):415–423. doi: 10.1177/10915818251340384 [DOI] [PubMed] [Google Scholar]
- 14.Jacob S, Boddu SHS, Bhandare R, Ahmad SS, Nair AB. Orodispersible films: current innovations and emerging trends. Pharmaceutics. 2023;15(12):2753. doi: 10.3390/pharmaceutics15122753 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Musazzi UM, Khalid GM, Selmin F, Minghetti P, Cilurzo F. Trends in the production methods of orodispersible films. Int J Pharm. 2020;576:118963. doi: 10.1016/j.ijpharm.2019.118963 [DOI] [PubMed] [Google Scholar]
- 16.Bitter I, Treuer T, Dilbaz N, et al. Patients’ preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. World J Biol Psychiatry. 2010;11(7):894–903. doi: 10.3109/15622975.2010.505663 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Galdas PM, Seidler ZE, Oliffe JL. Designing men’s health programs: the 5C framework. Am J Mens Health. 2023;17(4). doi: 10.1177/15579883231186463 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Hawkes S, Allotey P, Elhadj AS, Clark J, Horton R. The Lancet Commission on Gender and Global Health. Lancet. 2020;396(10250):521–522. doi: 10.1016/S0140-6736(20)31547-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Smith JA, Watkins DC, Griffith DM. Equity, gender and health: new directions for global men’s health promotion. Health Promot J Austr. 2020;31(2):161–165. doi: 10.1002/hpja.337 [DOI] [PubMed] [Google Scholar]
- 20.Hay K, McDougal L, Percival V, et al. Disrupting gender norms in health systems: making the case for change. Lancet. 2019;393(10190):2535–2549. doi: 10.1016/S0140-6736(19)30648-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data supporting the findings of this study are available from the corresponding author upon reasonable request.
